Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMENTUM: DNTH103 in adults with multifocal motor neuropathy
2024-513128-40-00Phase 2Authorised
- Sponsor
- Dianthus Therapeutics
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in multifocal motor neuropathy (MMN) comparing DNTH103 with Matching placebo to DNTH103 (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Planned start Feb 2025; status: authorised.
02
Drugs
claseprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on 2024-513128-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513128-40-00.